RE: Expectations for next Wed.6 Dec 2023 17:44
Agree Ben, it’ll be deals or a takeover. Or some bonkers universe where big pharma don’t care about Abakta, they get approval and start selling AVA6k and that funds 3996. It’d be difficult for the market to continue to value a business at £300/400m if they have a juicy revenue stream from a single indication. All roads lead to greatness, if the data backs it up. Let’s see what Wed brings. It’d be great if it’s released prior so that the Q&A will be more productive, but hey ho.